Evidence-Based Complementary and Alternative Medicine

Evidence-Based Complementary and Alternative Medicine / 2021 / Article
Special Issue

Nervous System Inflammatory Responses and their Natural Compounds/Extract-Derived Targets

View this Special Issue

Research Article | Open Access

Volume 2021 |Article ID 5543320 | https://doi.org/10.1155/2021/5543320

Francis Ackah Armah, Isaac Tabiri Henneh, Isaac Kingsley Amponsah, Robert Peter Biney, Fynn Malcolm, John Alake, Wisdom Ahlidja, Mustapha Abubakar Ahmed, Christian Kweku Adokoh, Genevieve Etornam Adukpo, Desmond Omane Acheampong, Peter K. Gathumbi, "Antidepressant and Anxiolytic Effects and Subacute Toxicity of the Aerial Parts of Psychotria ankasensis J.B.Hall (Rubiaceae) in Murine Models", Evidence-Based Complementary and Alternative Medicine, vol. 2021, Article ID 5543320, 18 pages, 2021. https://doi.org/10.1155/2021/5543320

Antidepressant and Anxiolytic Effects and Subacute Toxicity of the Aerial Parts of Psychotria ankasensis J.B.Hall (Rubiaceae) in Murine Models

Academic Editor: Md. Sahab Uddin
Received08 Jan 2021
Revised19 Mar 2021
Accepted06 May 2021
Published18 May 2021


Background. The present study aimed at validating the traditional use and toxicity profile of a methanolic extract of the aerial parts of Psychotria ankasensis in alleviating depression and anxiety disorders. Method. The antidepressant effect of methanolic extract of Psychotria ankasensis (PAE 30, 100, and 300 mg/kg, p.o.) was assessed in mice using the forced swim test (FST) and the tail suspension test (TST). The plant's anxiolytic potential was also evaluated in mice using the elevated plus-maze (EPM) and the open field tests (OFT). The subacute toxicity was assessed via oral administration of PAE at doses of 100, 300, and 1000 mg/kg in rats for 28 days. Results. PAE 100 and 300 mg/kg showed antidepressant-like properties by significantly (at least ) decreasing the frequency and duration of immobility in FST and TST. PAE (100 and 300 mg/kg) also showed a significant (at least ) anxiolytic effect in both EPM and OFT. In the EPM test, Emax for PAE and diazepam were 92.52 ± 40.11% and 85.95 ± 45.92%, respectively, whereas Emax was approximately 100% for both test drugs in the OFT. Subacute administration of PAE did not reveal any toxic effects with respect to organ weight index, haematological, serum biochemical, and histopathological parameters. Conclusions. Methanolic extract of P. ankasensis exhibited antidepressant-like and anxiolytic-like effects devoid of significant toxicity at the doses tested in murine models.

1. Background

Depression is one of the most common mental disorders that affects one out of every sixteen persons worldwide [1]. It is characterized by symptoms such as anhedonia, low self-esteem, and suicidality. It is a leading cause of a number of diseases or disability burden all over the world [2]. Antidepressants in clinical use, such as the selective serotonin reuptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs), are refractory in about 50% of patients, have delayed onset of action, and are accompanied by numerous side effects [3]. Besides, a high comorbidity exists between depression and anxiety, two mental diseases that reduce patients’ quality of life [4].

Anxiety disorder is a prevalent psychiatric condition that occurs in one-eighth of the world’s population making it a prominent research area in psychopharmacology [5]. Anxiety disorders possess a very high disease, social, and economic burden [6]. The use of medications such as benzodiazepines, SSRIs, beta-blockers, and monoamine oxidase inhibitors in treating anxiety disorders is limited by numerous side effects [7, 8]. For instance, the sudden withdrawal of benzodiazepines causes withdrawal syndrome characterized by olfactory and tactile disturbance, disorientation, and paresthesia [9]. These shortcomings create the need for alternative medications for anxiety and depression.

Over 2000 plant species within the Psychotria genus have been reported to affect the central nervous system (CNS) [10]. For instance, monoterpene indole alkaloids isolated from Psychotria suterella and Psychotria laciniata were found to significantly inhibit monoamine oxidases (MAO-A and MAO-B) obtained from rat brain mitochondria [11, 12]. The inhibition of the monoamine oxidase enzymes constitutes an important mechanism of action for antidepressants in the monoamine oxidase inhibitor class such as phenelzine [13]. A scientific study of Psychotria genus indicates that several species within this genus can mitigate neurodegenerative disorders in addition to their analgesic, antimutagenic, antioxidant, antiviral, antipyretic, and anti-inflammatory activities [10, 14]. In Ghana, the indigens within the communities surrounding the Ankasa Forest where the plant was first identified traditionally use Psychotria ankasensis aerial parts to treat infectious diseases [15]. Research on its medicinal properties is not widespread, and it is traditionally used in the treatment of anxiety and depression in Ghana. The present study considered the effects of Psychotria ankasensis methanolic extract on anxiety and depression as well as elucidating its toxicity profile in rodents.

2. Results

2.1. PAE Produced an Antidepressant-Like Effect in the Forced Swim Test

PAE 100 and 300 mg/kg significantly ( and , respestively) decreased the duration of immobility in the FST, but the frequency of immobility was not significantly altered (Figures 1(a) and 1(b)). Fluoxetine also produced a significant () decrease in immobility duration at 10 and 30 mg/kg (Figures 2(a) and 2(b)). Dose-response curves plotted produced ED50 values of 99.21 ± 1.83 and 2.71 ± 2.17 mg/kg for PAE and FLX, respectively (Figure 2(a)). The maximum efficacy (Emax) values were 83.69 ± 19.16 and 65.66 ± 12.56% for PAE and fluoxetine, respectively (see Figure 2(a)).

2.2. PAE Produced an Antidepressant Effect in the Tail Suspension Test

The oral administration of PAE 100 and 300 mg/kg resulted in a significant () decrease in immobility duration and frequency in the tail suspension test (Figure 3). Fluoxetine, 10 mg/kg () and 30 mg/kg () increased the duration and frequency of immobility compared to the control group. ED50 values obtained from the dose-response curves showed that the extract (ED50 = 36.28 ± 2.30) was less potent than fluoxetine (ED50 = 3.28 ± 1.75) (Figure 2(b)). On the other hand, the maximal efficacy (Emax) values of the extract and fluoxetine (Figure 2(b)) were 65.49 ± 9.72% and 67.81 ± 15.32%, respectively.

2.3. PAE Exerted Anxiolytic-Like Effect in the Elevated Plus-Maze Test

Results illustrated in Figure 4 show that there was a significant change in open arm entry between treatment groups in the elevated plus-maze test. The administration of PAE at 100 and 300 mg/kg significantly ( and , respectively) increased the duration mice spent in the open arms of the EPM compared to the control group (see Figure 4(a)). A similar observation was made with diazepam 1 mg/kg () and 3 mg/kg () as presented in Figure 4(c). The frequency of entry into the open arms was also significantly () increased at 300 mg/kg of PAE (Figure 44(b)), whereas diazepam could not increase it significantly (Figure 4(d)). ED50s for PAE and diazepam were 107.30 ± 4.45 and 2.71 ± 1.10 mg/kg, respectively. On the other hand, Emax for PAE and diazepam were 92.52 ± 40.11% and 85.95 ± 45.92%, respectively (Figure 5(b)).

2.4. PAE Produced an Anxiolytic-Like Effect in the Open Field Test

In the open field test, both PAE 100 mg/kg () and 300 mg/kg () and diazepam 1 mg/kg () and 3 mg/kg () significantly increased the duration mice spent in the open arms of the OFT compared to the untreated animals. The frequency of entry into the open arena was also significantly () increased by the highest doses of both PAE and diazepam (Figure 6). ED50 values obtained for PAE and diazepam in the test were 96.77 ± 4.43 and 2.37 ± 1.30, respectively. Emax values were, however, approximately 100% for both test drugs (Figure 5(a)).

2.5. Subacute Toxicity Evaluation of PAE

All the animals survived the 28-day experimental period. No notable physical changes were observed in any of the animals. Although body weight gain was observed across all treatment groups, there were no statistically significant differences between the treatment groups and the control group (Table 1). The average raw weights and weight indices of vital organs such as heart, liver, spleen, brain, kidneys, and lungs were not significantly different from the control group (Tables 2 and 3). Moreover, the haematological and biochemical analysis conducted on the animals after treatment with PAE (100, 300, and 1000 mg/kg, p.o.) revealed no significant () differences when compared with the control group (Tables 4 and 5).

DaysControlPAE 100 mg/kgPAE 300 mg/kgPAE 1000 mg/kg

0233.53 ± 2.40223.22 ± 3.01213.03 ± 2.12224.1 ± 2.03
14237.05 ± 4.10221.71 ± 1.21221.71 ± 2.90275.52 ± 4.70
28244.33 ± 5.33228.52 ± 5.40229.00 ± 3.80231.13 ± 6.30

Results are presented as Mean ± SEM (n = 5). One-way analysis of variance of all the datasets revealed no statistical significance ().

Parameter (g)ControlPAE 100 mg/kgPAE 300 (mg/kg)PAE 1000 mg/kg

Heart0.82 ± 0.050.62 ± 0.060.82 ± 0.030.74 ± 0.07
Liver6.57 ± 0.285.18 ± 0.346.86 ± 0.366.06 ± 0.27
Spleen0.75 ± 0.030.73 ± 0.110.91 ± 0.090.81 ± 0.06
L. kidney0.64 ± 0.040.53 ± 0.020.63 ± 0.050.59 ± 0.05
R. kidney0.64 ± 0.150.52 ± 0.040.69 ± 0.050.60 ± 0.04
Lungs1.94 ± 0.171.38 ± 0.031.77 ± 0.081.42 ± 0.14
Brain1.76 ± 0.111.81 ± 0.211.76 ± 0.041.82 ± 0.32

Results are presented as mean ± SEM (n = 5). One-way analysis of variance of all the datasets revealed no statistical significance ().

ParameterControlPAE 100 mg/kgPAE 300 (mg/kg)PAE 1000 mg/kg

Heart0.0034 ± 0.00020.0027 ± 0.00020.0036 ± 0.00020.0032 ± 0.0002
Liver0.0269 ± 0.00110.0227 ± 0.00150.0300 ± 0.00160.0262 ± 0.0012
Spleen0.0031 ± 0.00010.0032 ± 0.00050.0040 ± 0.00040.0035 ± 0.0003
Left kidney0.0026 ± 0.00020.0023 ± 0.00010.0027 ± 0.00020.0026 ± 0.0002
Right kidney0.0027 ± 0.00010.0023 ± 0.00020.0030 ± 0.00020.0026 ± 0.0002
Lungs0.0079 ± 0.00070.0060 ± 0.00010.0077 ± 0.00040.0062 ± 0.0006
Brain0.0072 ± 0.00020.0074 ± 0.00010.0072 ± 0.00030.0074 ± 0.0001

Organ weight index = organ weight/carcass weight. Results are presented as mean ± SEM (n = 5). One-way analysis of variance of all the datasets revealed no statistical significance ().

ParameterControlPAE 100 mg/kgPAE 300 (mg/kg)PAE 1000 mg/kg

WBC (109/L)14.92 ± 0.2914.75 ± 1.6515.75 ± 1.1115.60 ± 0.29
LYM (%)46.85 ± 5.8466.79 ± 4.4357.43 ± 4.7956.69 ± 4.13
MON (%)8.72 ± 1.5810.96 ± 0.1017.80 ± 0.2719.82 ± 2.60
NEU (%)37.45 ± 5.0525.21 ± 8.3922.90 ± 4.9222.67 ± 2.70
EOS (%)6.44 ± 1.022.50 ± 1.641.73 ± 0.493.15 ± 0.4542
BASO (%)0.36 ± 0.090.05 ± 0.010.20 ± 0.050.28 ± 0.04
LYM# (109/L)2.05 ± 0.466.21 ± 3.402.98 ± 0.722.81 ± 0.43
MON# (109/L)0.55 ± 0.220.99 ± 0.501.12 ± 0.130.82 ± 0.12
NEU# (109/L)1.04 ± 0.101.65 ± 0.621.53 ± 0.291.08 ± 0.09
EOS# (109/L)0.18 ± 0.010.15 ± 0.040.10 ± 0.030.15 ± 0.02
BASO# (109/L)0.01 ± 0.000.01 ± 0.000.01 ± 0.000.01 ± 0.01
RBC (1012/L)7.89 ± 0.088.07 ± 0.218.83 ± 0.608.61 ± 0.23
HGB (g/dL)14.92 ± 0.2914.75 ± 1.6515.75 ± 1.1115.60 ± 0.29
HCT (%)37.76 ± 0.7836.80 ± 3.3040.68 ± 3.7039.75 ± 1.00
MCV (fL)47.94 ± 0.8245.65 ± 2.9545.88 ± 1.2646.23 ± 0.30
MCH (pg)18.86 ± 0.3618.20 ± 1.6017.78 ± 0.4518.1 ± 0.37
MCHC (g/dL)39.6 ± 0.2440.00 ± 1.0039.00 ± 1.0839.25 ± 0.75
RDW (%)12.04 ± 0.2513.05 ± 0.8514.05 ± 0.3213.20 ± 1.64
RDW_SD (fL)44.62 ± 1.3842.50 ± 1.1046.25 ± 1.9642.35 ± 2.61
RDW_CV (%)12.04 ± 0.2613.05 ± 0.8514.05 ± 0.3213.2 ± 1.64
PLT (109/L)1041.00 ± 60.971281.00 ± 574.501341.00 ± 142.50961.00 ± 86.27
MPV (fL)4.70 ± 0.19245.30 ± 0.204.65 ± 0.094.33 ± 0.16
PDW (fL)6.88 ± 0.248.05 ± 2.357.50 ± 0.396.25 ± 0.30
PCT (%)0.48 ± 0.030.69 ± 0.330.62 ± 0.070.41 ± 0.04

Results are presented as mean ± SEM, (n = 5). One-way analysis of variance of all the datasets revealed no statistical significance (). WBC: white blood cell count, LYM: lymphocytes, MON: monocytes, NEU: neutrophils, EOS: eosinophils, BASO: basophils, RBC: red blood cell count, HGB: haemoglobin, HCT: haematocrit, MCH: mean corpuscular haemoglobin, MCHC: mean corpuscular haemoglobin concentration, MCV: mean corpuscular volume, PLT: platelets count, RDW: red blood cell distribution width, RDW_CV: red blood cell distribution width coefficient of variation, MPV: mean platelet volume, PDW: platelet distribution width, and PCT: plateletcrit.

ParameterControlPAE 100 mg/kgPAE 300 (mg/kg)PAE 1000 mg/kg

TBil (µmol/L)8.17 ± 0.249.06 ± 0.708.69 ± 0.787.86 ± 0.44
Dbil (µmol/L)3.62 ± 0.423.57 ± 0.243.78 ± 0.203.38 ± 0.19
TP (g/L)70.48 ± 2.4969.8 ± 1.2973.40 ± 3.3379.66 ± 4.65
ALB (g/L)28.90 ± 0.7429.1 ± 1.5229.10 ± 2.0130.70 ± 0.51
GLB (g/L)39.50 ± 1.3040.70 ± 2.0044.33 ± 1.9944.38 ± 1.54
A/G0.65 ± 0.080.72 ± 0.060.65 ± 0.050.62 ± 0.08
ALT (U/L)54.51 ± 4.6059.49 ± 7.3067.92 ± 6.3271.08 ± 5.15
ALP (U/L)79.56 ± 1.3077.55 ± 4.7575.53 ± 4.4578.24 ± 3.23
AST (U/L)95.02 ± 9.12116.30 ± 16.08113.40 ± 18.5099.68 ± 8.79
GGT (U/L)6.2 ± 0.587.67 ± 1.336.50 ± 1.567.60 ± 0.40
UREA (mmol/L)6.96 ± 0.505.77 ± 0.667.28 ± 1.316.76 ± 0.89
CREAT(µmol/L)145.00 ± 2.76119.30 ± 10.93130.10 ± 17.83134.70 ± 4.39
UA (µmol/L)33.66 ± 3.7230.48 ± 2.4027.33 ± 2.3828.30 ± 3.60
GLU (µmol/L)7.586 ± 0.8811.04 ± 1.777.79 ± 1.1111.20 ± 1.38
Ca (µmol/L)2.54 ± 0.022.64 ± 0.082.69 ± 0.062.58 ± 0.01
LDL (µmol/L)0.64 ± 0.080.72 ± 0.030.72 ± 0.070.64 ± 0.05
TG (µmol/L)1.01 ± 0.120.69 ± 0.091.03 ± 0.190.84 ± 0.09
CHOL (µmol/L)1.79 ± 1.001.58 ± 0.072.11 ± 0.141.82 ± 0.11
HDL C (µmol/L)0.63 ± 0.050.56 ± 0.030.88 ± 0.030.75 ± 0.08

Results are presented as Mean ± SEM (n = 5): one-way analysis of variance of all the datasets revealed no statistical significance (). TBill: total bilirubin, DBill: direct bilirubin, TP: total proteins, ALB: albumin, GLB: globulins, ALT: alanine aminotransferase, ALP: alkaline phosphatase, AST: aspartate aminotransferase, CREAT: creatinine, UA: uric acid, GLU: glucose, and TG: triglycerides, CHOL: cholesterol, LDL: low-density lipoprotein, HDL C: high-density lipoprotein C, Ca: calcium, GGT: gamma GT, and A/G: albumin-to-globulins ratio.
2.5.1. Histopathology

(1) There were no significant gross and histopathology lesions that could be attributed to the effects of the plant extract in the liver. Most hepatocytes had a normal structure with a large vesicular nucleus and abundant pink cytoplasm. However, a few hepatocytes that were sparsely spread in the tissue contained a dark condensed nucleus and a more eosinophilic (pinker) and less abundant cytoplasm. This was consistent with single hepatocyte necrosis (death), in the midst of many normal ones, across the entire liver (Figure 7). This represents mild randomly distributed single-cell hepatocellular necrosis. The biliary system, vasculature, and supportive tissues and cells of the defense system in the liver were in normal status. There were moderate distensions of few blood vessels, consistent with mild congestion (Figure 7). These observations occurred in the test and control groups and could therefore not be linked with the effects of the extract.

(2) Renal histology revealed no abnormalities in test and control. The structure of the tubules, glomerulus, and interstitial tissues was normal in the entire kidney (Figure 8). A few scattered blood vessels were moderately distended with blood (congested). Parenchyma had normal architecture, and all tissues were in apparently normal morphology.

(3) The lungs showed no abnormalities. Across the tissue, alveoli (arrow) were empty in some parts of the tissue, but some had a slightly larger volume (emphysema). In contrast, others were smaller (atelectasis), and the interalveolar wall was thicker and had more cell density. These are considered as nonlesions since they also occurred in control animals. Bronchial-associated lymphoid tissue (BALT (P)) was prominent. Morphological features of the tissues were the same as in tissues from control animals (Figure 9).

(4) The spleen, brain, and heart showed no abnormalities. The morphology of the tissues in the spleen was similar to that of control animals. In all cases, the red and white pulp was normal in structure, the latter being densely populated with lymphoid cells in Malpighian follicles (Figure 10).

A section through the midbrain showed a typical Ammon’s horn of the hippocampus (broad arrow) with a normal superstructure (Figure 11). A few neurons individually had condensed nucleus and cytoplasm that stains eosinophilic (c and d arrow), a change that was consistent with an acute ischemic injury of affected neurons. Coincidentally, it also occurred in both treatment and control groups. Therefore, as in the liver, it could not be associated with the extract but may be an external factor, probably acute anoxia during euthanasia. Additionally, the heart showed no abnormalities as the structure of the myocardium and intermuscular tissues appeared normal in the treatment and control groups (Figure 12).

2.6. Phytochemical Analysis

Psychotria ankasensis was found to contain alkaloids, triterpenoids, steroids, tannins, anthraquinone glycosides, saponins, and reducing sugars (Table 6). In an attempt to standardise the extract to afford repeatability or further study, an HPLC chromatogram was developed (Figure 13). The HPLC fingerprint showed 45 peaks as presented (Figure 13 and Table 7). Two significant peaks (with retention times of 30.495 and 32.485 minutes) were selected as marker peaks for the identification of Psychotria ankasensis. A detailed result showing the retention times, areas under the curves, heights, and areas (%) has been supplied in Table 7.


Anthraquinone aglycones+
Fatty acids+
Reducing sugars+

The symbols (+) indicates present and (−) indicates absent.

Peak#Ret. timeAreaHeightMarkConc.Area (%)


3. Discussion

Psychotria ankasensis showed marked antidepressant-like activity. It significantly (at least ) reversed the increased duration of immobility induced by the stressful situation of forced swimming and tail suspension test (Figures 13). The extract exhibited similar efficacy as the 1st line antidepressant drug, fluoxetine, in both the tail suspension and forced swim test. This highlights the potential of the extract towards developing and validating indigenous plant remedies for depression and anxiety.

The forced swim and tail suspension tests were employed in these tests as they have been commonly used in depression research due to their high predictive potential [16]. Both tests utilise the principle of behavioural despair, which is similar to human depression as the animals become immobile following numerous unsuccessful attempts to escape from the inescapable condition. The tests’ validity is based on the fact that almost all the antidepressants in clinical use significantly decrease the duration and frequency of immobility in both tests [16]. The effect observed within the study suggests it could be a source of novel phytochemicals which could be isolated and characterized to provide valuable leads for optimization and further development in the antidepressant drug discovery pipeline.

Anxiety disorder is reported to be the most predominant comorbid condition of depression [17]. Antidepressants, for example, the selective serotonin reuptake inhibitors, are also known to exhibit a significant anxiolytic effect. Therefore, the extract's anxiolytic actions were assessed using the elevated plus-maze and the open field tests.

The elevated plus-maze is used to test mice's aversion towards falling from a high unprotected arm of the maze. This approach-avoidance test exploits the innate exploratory drive of rodents against their natural fear of unprotected environments. A test compound's ability to tilt this balance towards favouring the exploratory drive with minimal anxiety is predictive of potential anxiolytic-like effects [18]. Thus, administration of benzodiazepine and other anxiolytics inreaseses the exploration of the unprotected arms of the maze by mice treated with anxiolytics compared to naivemice [19]. As observed in the study, the administration of PAE and diazepam an hour before the test resulted in a significant increase in duration () and frequency () of entry into the unprotected well-illuminated open arms of the test (Figure 4). This gives an indication that PAE is a potential anxiolytic agent.

In the open field test, the introduction of the mice to a relatively larger, well-illuminated, and novel arena compared to their breeding or natural environment is known to induce anxiety-like behaviours such as increased thigmotaxis, defecation as well as increased time spent in the closed dark corners. The ability of test compounds to increase the time spent in the centre of the apparatus and the frequency of central arena entry but not the corners or periphery has been recognised as an anxiolytic effect [7, 8]. This was confirmed by diazepam (Figure 6), which is an established anxiolytic drug in clinical use. PAE also significantly () increased the duration and frequency of entry into the centre arena, just as was observed with diazepam (Figure 6). This gives further confirmation of an anxiolytic-like effect and confirms the results seen in the EPM. PAE actually exhibited a comparable efficacy as diazepam, the current first-line drug for treating many types of anxiety (Figure 5). This gives credence to the plant's traditional usage and reveals its potential for further exploration for novel phytocompounds with anxiolytic activity.

With the antidepressant-like and anxiolytic-like efficacy of P. ankasensis established, there was the need to assess its toxicity since safety is the highest cause of attrition in the drug discovery and development pipeline. There were no statistically significant differences between the organ weights of the liver, kidney, lungs, spleen, and heart of the treated groups compared to the control group (Table 2) in the subacute activity. Similarly, the average weight indices of all the organs assessed did not change significantly (Table 3). It is known that toxic substances' consumption can substantially alter the weight indicies of these vital organs [20]. Therefore, the insignificant changes give an early indication that the plant extract may not be toxic to these essential organs.

PAE's apparent safety was further confirmed by evaluating serum biochemical, gross anatomical, and histological markers of organ damage. Haematological and biochemical parameters evaluation constitute an essential indicator in evaluating xenobiotic toxicity in animals [2123]. Results obtained from the haemogram showed the extract exerted no deleterious effect on whole blood cell count parameters such as PCV, MCH, MCV, MCHC, and haemoglobin in the treated groups compared to the control group. Also, RBC, Hb, PCV, MCV, MCH, and MCHC were all not significantly affected by the treatment. The absence of any significant changes on RBC, MCV, MCHC, PCV, MCH, and HCT may be because there were no changes in the red blood cells' erythropoiesis and morphology, as well as the integration of haemoglobin into red blood cells [24]. Also, there were no significant differences in platelet, lymphocytes, monocytes, and neutrophils count in the treated group compared to the control group. These insignificant changes in haematological parameters are an indication of the safety of the test substances, as has been suggested in other studies [25].

Biochemical parameters such as serum electrolytes and other secretory enzymes and proteins constitute additional vital biomarkers for determining the functional capacity of the various organs of the body [23]. For instance, the liver is known to play a crucial role in drug metabolism. As such, alterations in these biochemical parameters can significantly affect the normal function of the liver [24]. Alternationin lipid and plasma enzymes such as AST (aspartate aminotransferase) and ALT (alanine aminotransferase) constitute an important index for identifying injured hepatocytes. At the same time, the elevation of ALP (alkaline phosphatase) and GGT (gamma-glutamyl transferase) in serum indicates liver injuries that cause bile stasis [26]. However, the present study results did not show any significant alterations in the tested liver biochemical enzyme markers that could be attributed to the subacute administration of P. ankasensis extract. Again, bilirubin is an important endogenous organic anion obtained from haemoglobin breakdown. It is a product of haem's metabolic degradation from senescent red blood cells and is one of the commonly used marker in liver function test [27]. The present study indicates no statistical difference in bilirubin levels between the control group and the treatment groups. It also worth-mentioning that most serum proteins (other than immunoglobulins), such as albumin, fibrinogen, α, and β globulins, and other coagulation factors are synthesized from the parenchymal cells of the liver [28, 29]. Quantitatively, albumin is among the vital plasma proteins synthesized by the liver and is used to evaluate liver function [24]. The result showed no statistical difference between the treatment group and the control groups. These findings were supported by the histopathological examination of the liver (Figure 7), which revealed that most of the hepatocytes showed a regular architecture with a large vesicular nucleus and abundant pink cytoplasm. Although mild single-cell hepatocellular necrosis was seen in the liver tissues of few rats in both treatment and control groups, most hepatocytes were normal. As such, the liver function would not be affected by such mild single-cell necrosis of hepatocytes. Generally, liver function decreases if more than 75% of hepatocytes are dead. Since liver tissue from control animals also showed the same response as in other groups of animals, the observed mild necrosis of hepatocytes could not have been caused by the extract but an external factor which is likely to be the euthanizing agent.

Again, renal function parameters are used to evaluate the normal functioning of different sections of the nephrons [30]. Similarly, the serum concentrations of uric acid, electrolytes, creatinine, and urea provide an understanding of the toxic effects produced by test substances on the tubular and glomerular functions of the kidney [24]. Kidney enzymes and biochemical markers such as creatinine, urea, uric acid, and electrolytes (Table 4) observed in the experimental group were not significantly different from the control group (). Histopathological examination of the kidney (tubules, glomerulus, and interstitial tissues) revealed no abnormality as PAE treated groups were similar to the control group (Figure 8).

The present study (Figure 9) also showed that P. ankasensis could not induce any pathological alterations in the tissues of the lungs of the experimental group as no abnormalities were seen. Although the treatment groups' alveoli appeared empty in some parts of the tissue, with some having considerably larger lumen while others were smaller. Also, the interalveolar wall seemed thicker. All these could be considered nonlesions since they also occurred in the control group. Also, Bronchial-Associated Lymphoid Tissue (BALT) was prominent in all groups. Morphological features of the tissues were the same as in tissues from the control group.

Histological examination of haematoxylin and eosin-stained tissues from the spleen of animals treated with P. ankasensis indicated no tissue morphology abnormalities. Since no significant difference was seen in the treated group compared to the control group, it suggests that P. ankasensis has no damaging effect on the spleen (Figure 10).

Based on the brain's histopathological result (Figure 11), the study did not reveal any damage to the midbrain. Also, the structures of the brain are normal. However, few neurons have a condensed nucleus and cytoplasm that show eosinophilic changes consistent with an acute ischemic injury of affected neurons. Since it was observed in sections of the treated group and the control group, it cannot be associated with the P. ankasensis extract. Still, it may be an external factor such as anoxia associated with euthanasia.

Changes in concentrations of significant lipids such as cholesterol, low-density lipoproteins (LDL), high-density lipoprotein (HDL), and triglycerides provide a useful indicator of cardiac function [30] as it is associated with the predisposition of the heart to atherosclerosis and its attended cardiac complications. High levels of lipids except HDL are associated with increased risk of atherosclerosis with elevated LDL levels, and triglycerides are associated with coronary artery disease [21]. In this study, there was no significant () difference in the lipid profile of the treatment groups compared to the control group (Table 4). Also, no abnormal pathological alterations were detected during the histopathological examination of the heart. The morphology of tissues of the heart in the treated groups was not different from the control group (Figure 12).

Phytochemicals such as alkaloids, triterpenoids, steroids, tannins, anthraquinone glycosides, saponins, and reducing sugars were present in the plant. The HPLC chromatogram of the extract developed (Figure 13) will serve as a template for tracking the extract for further research or quality control of any potential phytomedicine from the plant. The presence of these phytochemicals has been shown to account for the efficacy and toxicity of medicinal plants [31, 32]. Specifically, β-carboline and monoterpene indoles alkaloids isolated from several Psychotria species have been shown to produce inhibitory properties against monoamine oxidase proteins, which are enzymatic targets depression and anxiety [33]. As a result, the pharmacological activity observed in this study can be attributed to the presence of the above phytochemicals. Our further research will focus on isolating the compounds responsible for the observed effect. Also, the mechanisms underpinning the observed anxiolytic-like and antidepressant-like effect will be explored in chronic animal models.

4. Conclusion

P. ankasensis extract exhibited antidepressant and anxiolytic effects in murine models. There were no significant toxic effects associated with the doses of the extract used in this study.

5. Materials and Methods

5.1. Plant Material Collection

Aerial parts of Psychotria ankasensis were collected from the Ankasa forest (5°17′00.0″N, 2°39′00.0″W) in Jomoro District, Western Region of Ghana in February 2019. The plant was identified and authenticated by a botanist at the Herbarium of School of Biological Sciences, University of Cape Coast, and a voucher specimen preserved (identification number FAA/DR/003).

5.2. Preparation of the Extract

The aerial parts of Psychotria ankasensis were air-dried for three weeks and then pulverized using a hammer mill to obtain a fine powder. An amount of 1200 g of the powdered sample was weighed and cold macerated with 4000 mL of absolute methanol for 72 h. It was filtered and the resulting filtrate concentrated using a rotary evaporator at a reduced temperature of 40˚C. The extract was further dried in a desiccator containing activated silica until it was thoroughly dried to to obtain a dark gummy extract (PAE, 84.1 g). It was subsequently stored in a refrigerator, and the required doses were reconstituted immediately before drug administration.

5.3. Drugs and Chemicals

Methanol was obtained from the British Drug House (Poole, UK), whereas diazepam, fluoxetine, tween 80, and other reagents used were of analytical grade bought from Sigma-Aldrich Inc., St. Louis, MO, USA. Emulsions of the extract, fluoxetine and diazepam were prepared using tween 80 q.s. as a surfactant. Control group animals received vehicle which comprised 1% tween 80 in distilled water. The selection of doses and times of administration were based on the findings from preliminary studies on the extract.

5.4. Experimental Animals

Male Sprague-Dawley rats (8–10 weeks old, 190-240 g), as well as Imprint Control Region (ICR) mice (7 weeks old, 20-25 g), were used in this experiment. These animals were purchased from the Noguchi Memorial Institute for Medical Research (NMIMR), Ghana, and kept at the Department of Biomedical Sciences' animal house, University of Cape Coast (UCC). They were acclimatised for two weeks before the experiments under standard laboratory conditions of room temperature (25 ± 1°C) and relative humidity (40 ± 10%) with a 12/12 h light/dark cycle. The animals were housed in stainless steel cages with softwood shaving as bedding, cleaned, and maintained daily and fed with standard commercial pelleted rodent feed (Floor Mills of Ghana Limited, Tema, Ghana) and water ad libitum during acclimatisation and experimental periods. It was ensured that doses of extract, positive control drugs, and vehicle did not exceed 1 mL/100 g body weight (for mice) or 2 mL/100 g body weight (for rats). The National Institute of Health Guidelines for the Care and Use of Laboratory Animals were adhered to throughout the study. All procedures employed in this study were approved by the University of Cape Coast Ethical Review Board (clearance number UCCIRB/CHAS/2018/14).

5.5. Evaluation of the Antidepressant Effect of PAE
5.5.1. Forced Swim Test (FST)

A method initially described was adopted for the study [34]. Forty-nine (49) mice were randomly grouped into seven (n = 7). One hour after PAE 30, 100, or 300 mg/kg, fluoxetine 3, 10, or 30 mg/kg or vehicle10 mL/kg administration using oral gavage, mice were carefully placed individually into transparent plastic cylinders (height = 30 cm; diameter = 15 cm), filled with water (25 ± 1°C) up to a depth of 20 cm. Each mouse was allowed to swim for 6 min period and captured with a camcorder hanged above the cylinder. The mice were removed from the water after each test session, dried with a towel, and placed near a heat source until they were completely dried. The duration and frequency of immobility during the last 4 min of the test were quantified using JWatcher software (Version 1.0TM).

5.5.2. Tail Suspension Test (TST)

The test was performed following a protocol described [16]. Briefly, mice were randomly assigned to seven groups (n = 7) and given PAE 30, 100, or 300 mg/kg, fluoxetine 3, 10, or 30 mg/kg, or vehicle10 mL/kg orally via a gavage. One hour after administration of the various treatments, the tails of the mice were suspended on a horizontal bar mounted 50 cm from a bench. After the suspension on the bar (i.e., climbing and swinging), the movement of the mice was recorded for 6 min with a camcorder. The duration and frequency of immobility of the mice for the entire 6 min session were tracked and quantified using the JWatcher Version 1.0® software.

5.6. Evaluation of the Anxiolytic-Like Effect of PAE
5.6.1. Elevated Plus-Maze (EPM) Test

A procedure previously described [35] was used with some modifications. Briefly, the apparatus was made up of a typical central square platform (5 × 5 cm) with an extension of two fenced arms (15 × 5 × 30 cm3) facing each other and another extension of two unfenced arms perpendicular to the fenced arms (15 × 5 cm2). To prevent the mice from falling off the unfenced arm of the maze, a 0.5 cm rim of Plexiglas enclosed the borders of the open arms. The whole apparatus was elevated 50 cm above the ground. The mice were divided into seven groups of seven mice each and pretreated with either PAE 30, 100, or 300 mg/kg, p.o. or the reference drug, diazepam 0.3, 1, and 3 mg/kg, p.o orvehicle, 10 mL/kg; p.o. The mice were placed individually in the centre of the maze facing the open arm at the start of the experiment. Their behavior was videotaped for 5 mins using a digital camera placed 75 cm above the maze and tracked for frequency duration spent in the open or closed arms using JWatcher.

5.6.2. Open Field Test (OFT)

A previously described method was followed [18]. Sixty minutes after oral administration of the various treatment to their respective groups, as indicated in the EPM test above, mice were placed individually in the centre of the open field. The apparatus was made of a wooden box (60 × 60 × 60 cm3) divided into 16 squares (15 × 15 cm2) and well illuminated. The four inner squares in the centre were deemed centre arena. The remaining 12 squares on the periphery, along the walls, and corners were considered a peripheral arena. Each mouse was recorded for 5 min with a camera. The frequency and time spent in each arena were tracked and quantified using the JWatcher.

5.7. Subacute Toxicity Evaluation of PAE

An earlier described method [36] was followed. Twenty Sprague-Dawley rats were randomly grouped into four groups (A, B, C, and D) of five rats each. Group A animals were orally administered with 10 mL/kg of vehicle once daily for 28 days, whereas groups B, C, and D received PAE at 100 mg/kg, 300 mg/kg, and 1000 mg/kg, respectively, for 28 days. The rats were observed twice daily for morbidity and mortality throughout the 28 days. All the animals had free access to food and water. They were weighed on days 0, 14, and 28 using a digital weighing balance (Sartorius Lab Instruments GmbH & Co. Goettingen, Germany). On the 29th day, Euthanasia was achieved by inhalation method as follows. Cotton soaked with diethyl ether was placed in a clean glass chamber and covered to achieve saturation within the chamber. The animals were then placed in the chamber one animal at a time and covered until total loss of consciousness was achieved. Loss of consciousness was rapid and painless. On average, the onset of sedation was 5 seconds. Blood samples were collected from the left ventricle of the heart. An amount of 1 ml of the blood was collected into EDTA tubes for the haematological analyses. Another 4 mL of blood was collected into gel separator tubes for biochemistry analyses.

5.7.1. Haematological Analysis

Blood samples were analysed for erythrocyte count (RBC), haemoglobin (Hb), haematocrit (HCT), mean corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), mean corpuscular volume (MCV), platelets count (PLC), leukocyte count (WBC), and their differentials using the autohaematology analyser (URIT-5250Vet, China).

5.7.2. Biochemical Analysis

Samples collected for biochemistry analyses were centrifuged at 10 mins at 3000 rpm to obtain the serum. The serum obtained was assayed for the lipid profile, total proteins, albumin, globulins, alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), creatinine, urea, and blood urea nitrogen using an auto biochemistry analyser (URIT-8021AVet, China).

5.7.3. Necropsy and Histology of Vital Organs

On the 29th day of the experiment, surviving animals were weighed and then euthanised for autopsy. Animals were put under heavy sedation by diethyl ether inhalation as described above in 5.7. A complete systematic autopsy was conducted, and gross lesions were recorded. Vital organs, namely, kidneys, liver, spleen, lungs, heart, and brain, were weighed using a digital weighing balance (Sartorius Lab Instruments GmbH & Co. Goettingen, Germany). Samples for histopathology were taken from organs with gross lesion and the following vital organs, kidneys, liver, spleen, lungs, heart, and brain, and fixed in 10% phosphate-buffered formalin for 24 hrs. Fixed tissues were processed for routine histopathology, embedded in paraffin, sectioned at 4-5 µm, and stained in haematoxylin and eosin [37]. Sections were examined using an Olympus microscope mounted with a live view digital SLR camera (E-330), and photomicrographs were taken.

5.8. Phytochemical Screening

The qualitative phytochemical test was performed on the Psychotria ankasensis powder according to methods described by Harborne [38].

5.9. HPLC Fingerprint of the Extract

A Shimadzu LC-20AD with SPD- 20AV UV-VIS Detector was used for the test. The mobile phase comprised 0.10 M acetic acid: acetonitrile using gradient elution. The percentages and times of varying the acetonitrile have been supplied in Table 8. A solution of 10 mg/mL solution of PAE was constituted using methanol. A volume of 10 µL of the extract (10 mg/mL) was injected into the columns and allowed to run for 45 min at a flow rate of 0.5 mL/min, under a pump pressure of 1700 Psi and a temperature of 40°C. The chromatograms obtained were detected at a wavelength of 256 nm and the retention times, areas under curve, concentrations, heights, and areas (%) of the chromatograms were then determined.

Time% composition of acetonitrile


5.10. Statistical Analysis

Data has been presented as mean ± standard error of the mean (SEM). Graphpad® Prism Version 7.0 (GraphPad Software, San Diego, CA, USA) for Windows was used to perform all statistical analysis with considered statistically significant for all tests. Differences between treatment groups were determined using one-way analysis of variance followed by Tukey’s post hoc test. Dose-response curves were plotted using an iterative curve fitting method which follows a nonlinear regression four-parameter logistic equation as follows:where y is the dependent variable and x is the independent variable. The four parameters used were a  is  the minimum value that can be obtained, b is Hill’s slope of the curve, c is the point of inflection, and d is the maximum value that can be obtained. With the aid of the above equations, ED50s were estimated using GraphPad® Software, San Diego, CA, USA.

5.11. Limitation of the Study

Authors do believe that this study is not without limitations and that the data presented therein should be interpreted with the challenges in view. Firstly, acute rodent behavioural models were employed in the study which are highly predictive models for depression and anxiety. The models do not induce significant structural modifications in the brain within the short time; hence, our decision not to perform histopathological/immunohistochemical assessment of brain areas implicated in depression. Our further research focuses on the effect of the extract in chronic models of depression and anxiety. Secondly, ether anaesthesia was employed as euthanasia procedure in the study. Although this method has some ethical implication due to its irritatory effect, we are also aware that all other euthanasia methods have their limitations. We ensured that any effect reported in the study was not attributable to the euthanasia method by subjecting all animals in the control and treatment groups to the same euthanasia method.


EPM:Elevated plus-maze
FST:Forced swim test
H&E:Hematoxylin and eosin
NMIMR:Noguchi Memorial Institute for Medical Research
OFT:Open field test
PAE:Psychotria ankasensis extract
TST:Tail suspension test.

Data Availability

All data generated or analysed during this study are included within this manuscript.

Ethical Approval

Ethical approval was obtained from the University of Cape Coast Institution Review Board.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

FAA is involved in conception and design of the study, supervision of data collection and analysis, and revision of the manuscript for important intellectual content. ITH is involved in conception and design of the study, data collection and analysis, and drafting of the manuscript. PKG, IKA, and RPB contributed to the analysis and interpretation of the data and corrected and improved the scientific quality of the manuscript. MAA and FM contributed to data collection and analysis. WA and JA contributed to data collection and analysis as well as drafting of the manuscript. CKA, DOA, and GEA reviewed the manuscript and corrected and improved the manuscript's scientific quality. All authors read and approved the final manuscript for submission.


The technical assistance of John Kofi Afortude and Kwabena Darko Adu is appreciated.


  1. C. Otte, S. M. Gold, B. W. Penninx et al., “Major depressive disorder,” Nature Reviews Disease Primers, vol. 2, no. 1, pp. 1–20, 2016. View at: Publisher Site | Google Scholar
  2. S. L. James, D. Abate, K. H. Abate et al., “Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017,” Lancet, vol. 392, no. 10159, pp. 1789–1858, 2018. View at: Google Scholar
  3. J. Konduru, “A review on anti-depressant drugs,” Advances in Pharmacoepidemiology & Drug Safety, vol. 3, no. 1, pp. 1-2, 2014. View at: Publisher Site | Google Scholar
  4. E. W. de Heer, M. M. J. G. Gerrits, A. T. F. Beekman et al., “the association of depression and anxiety with pain: a study from NESDA,” PLoS One, vol. 9, no. 10, Article ID e106907, 2014. View at: Publisher Site | Google Scholar
  5. J.-A. Min, Y.-E. Jung, D.-J. Kim et al., “Characteristics associated with low resilience in patients with depression and/or anxiety disorders,” Quality of Life Research, vol. 22, no. 2, pp. 231–241, 2013. View at: Publisher Site | Google Scholar
  6. D. Isacson, K. Bingefors, and L. Von Knorring, “The impact of depression is unevenly distributed in the population,” European Psychiatry, vol. 20, no. 3, pp. 205–212, 2005. View at: Publisher Site | Google Scholar
  7. V. Gupta, P. Bansal, S. Kumar, R. Sannd, and M. Rao, “Therapeutic efficacy of Phytochemicals as anti-anxiety-a review,” Journal of Pharmacy Research, vol. 3, no. 1, pp. 174–179, 2010. View at: Google Scholar
  8. J. F. Cryan and F. F. Sweeney, “The age of anxiety: role of animal models of anxiolytic action in drug discovery,” British Journal of Pharmacology, vol. 164, no. 4, pp. 1129–1161, 2011. View at: Publisher Site | Google Scholar
  9. T. T. Faustino, R. B. d. Almeida, and R. Andreatini, “Plantas medicinais no tratamento do transtorno de ansiedade generalizada: uma revisão dos estudos clínicos controlados,” Revista brasileira de psiquiatria, vol. 32, no. 4, pp. 429–436, 2010. View at: Publisher Site | Google Scholar
  10. A. Marques de Oliveira, R. P. Lyra Lemos, and L. M. Conserva, “β-Carboline alkaloids from Psychotria barbiflora DC. (Rubiaceae),” Biochemical Systematics and Ecology, vol. 50, pp. 339–341, 2013. View at: Publisher Site | Google Scholar
  11. C. Dos Santos Passos, T. C. Soldi, R. Torres Abib et al., “Monoamine oxidase inhibition by monoterpene indole alkaloids and fractions obtained from Psychotria suterella and Psychotria laciniata,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 28, no. 3, pp. 611–618, 2013. View at: Publisher Site | Google Scholar
  12. C. S. Passos, C. A. Simões-Pires, A. Nurisso et al., “Indole alkaloids of Psychotria as multifunctional cholinesterases and monoamine oxidases inhibitors,” Phytochemistry, vol. 86, pp. 8–20, 2013. View at: Publisher Site | Google Scholar
  13. T. Sub Laban and A. Saadabadi, “Monoamine oxidase inhibitors (MAOI),” 2020, http://www.ncbi.nlm.nih.gov/pubmed/30969670. View at: Google Scholar
  14. A. T. A. Pimenta, D. E. A. Uchôa, R. Braz-Filho, E. R. Silveira, and M. A. S. Lima, “Alkaloid and other chemical constituents from Psychotria stachyoides Benth,” Journal of the Brazilian Chemical Society, vol. 22, no. 11, pp. 2216–2219, 2011. View at: Publisher Site | Google Scholar
  15. I. Asiama, G. Komlaga, F. Tayman et al., “Phytochemical screening and biological activity studies on methanolic extract of Psychotria ankasensis,” International Research Journal of Pure and Applied Chemistry, vol. 5, pp. 159–162, 2010. View at: Google Scholar
  16. S. K. Kulkarni and A. Dhir, “Effect of various classes of antidepressants in behavioral paradigms of despair,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 31, no. 6, pp. 1248–1254, 2007. View at: Publisher Site | Google Scholar
  17. R. c. Kessler, “The global burden of anxiety and mood disorders: putting ESEMeD findings into perspective,” The Journal of Clinical Psychiatry, vol. 68, no. 2, pp. 10–19, 2007. View at: Publisher Site | Google Scholar
  18. R. P. Biney, C. K. Benneh, J. O. Kyekyeku, E. O. Ameyaw, E. Boakye-Gyasi, and E. Woode, “Attenuation of anxiety behaviours by xylopic acid in mice and zebrafish models of anxiety disorder,” UK Journal of Pharmaceutical Biosciences, vol. 6, no. 3, p. 7, 2018. View at: Publisher Site | Google Scholar
  19. J. N. Crawley, P. J. Marangos, S. M. Paul, P. Skolnick, and F. K. Goodwin, “Interaction between purine and benzodiazepine: inosine reverses diazepam-induced Stimulation of mouse exploratory behavior,” Science, vol. 211, no. 2, pp. 725–727, 1981. View at: Google Scholar
  20. G. Owusu, M. Antwi-Adjei, and I. Henneh, “Pentobarbitone-induced sleeping time and sub-acute toxicity studies of Trichilia monadelpha aqueous extract,” International Journal of Basic and Clinical Pharmacology, vol. 5, no. 6, pp. 2352–2356, 2016. View at: Publisher Site | Google Scholar
  21. M. T. Yakubu, M. A. Akanji, and A. T. Oladji, “Alterations in serum lipid profile of male rats by oral administration of aqueous extract of Fadogia agrestis stem,” Research Journal of Medicinal Plants, vol. 2, no. 2, pp. 66–73, 2008. View at: Google Scholar
  22. P. Mag, M. T. Yakubu, M. A. Akanji, and A. T. Oladiji, “Hematological evaluation in male albino rats following chronic administration of aqueous extract of Fadogia a grestis stem,” Pharmacognosy Magazine, vol. 3, no. 9, pp. 34–38, 2007. View at: Google Scholar
  23. M. T. Yakubu, L. S. Bilbis, M. Lawal, and M. A. Akanji, “Evaluation of selected parameters of rat liver and kidney function following repeated administration of yohimbine,” Biokemistri, vol. 15, no. 2, pp. 50–56, 2003. View at: Google Scholar
  24. A. N. Ukwuani, M. G. Abubakar, S. W. Hassan, and B. M. Agaie, “Toxicological studies of hydromethanolic leaves extract of grewia crenata,” IJPSDR, vol. 4, no. 4, pp. 245–249, 2012. View at: Google Scholar
  25. D. Konja, I. T. Henneh, S. Badu-Nyarko, S. A. Akwetey, E. Ameyaw, and M. Ekor, “Safety concern following sub-acute exposure to the popular food additives, sorghum bicolor and saltpetre, either separately or in combination in sprague-dawley rats,” Pharmacologia, vol. 8, no. 3, pp. 95–104, 2018. View at: Publisher Site | Google Scholar
  26. M. Labib, S. Palfrey, E. Paniagua, and R. Callender, “The postoperative inflammatory response to injury following laparoscopic assisted vaginal hysterectomy versus abdominal hysterectomy,” Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, vol. 34, no. 5, pp. 543–545, 1997. View at: Publisher Site | Google Scholar
  27. P. Jamjute, A. Ahmad, T. Ghosh, and P. Banfield, “Liver function test and pregnancy,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 22, no. 3, pp. 274–283, 2009. View at: Publisher Site | Google Scholar
  28. B. R. Thapa and W. Anuj, “Liver function tests and their interpretation,” Indian Journal of Pediatrics, vol. 74, no. 4, pp. 663–671, 2007. View at: Publisher Site | Google Scholar
  29. X. Li, H. Yang, J. Xiao et al., “Network pharmacology based investigation into the bioactive compounds and molecular mechanisms of Schisandrae Chinensis Fructus against drug-induced liver injury,” Bioorganic Chemistry, vol. 96, pp. 1–23, 2020. View at: Publisher Site | Google Scholar
  30. A. O. Abolaji, A. H. Adebayo, and O. S. Odesanmi, “Effects of ethanolic fruit extracts of parinari polyandra (rosceae) on serum lipid profile and some electrolytesin pregnant rabbits,” Research Journal of Medicinal Plants, vol. 1, 2007. View at: Publisher Site | Google Scholar
  31. E. G. de Mejía and M. V. Ramírez-Mares, “Ardisia: health-promoting properties and toxicity of phytochemicals and extracts,” Toxicology Mechanisms and Methods, vol. 21, no. 9, pp. 667–674, 2011. View at: Publisher Site | Google Scholar
  32. R. Bahramsoltani, M. H. Farzaei, M. S. Farahani, and R. Rahimi, “Phytochemical constituents as future antidepressants: a comprehensive review,” Reviews in the Neurosciences, vol. 26, no. 6, pp. 699–719, 2015. View at: Publisher Site | Google Scholar
  33. N. O. Calixto, S. D. Pinto, S. Vanderlan, and A. C. P. Bolzani, “The genus psychotria: phytochemistry, chemotaxonomy, ethnopharmacology and biological properties,” Journal of the Brazilian Chemical Society, vol. 27, no. 8, pp. 1355–1378, 2016. View at: Google Scholar
  34. R. D. Porsolt, G. Anton, N. Blavet, and M. Jalfre, “Behavioural despair in rats: a new model sensitive to antidepressant treatments,” European Journal of Pharmacology, vol. 47, no. 4, pp. 379–391, 1978. View at: Publisher Site | Google Scholar
  35. S. Pellow and S. E. File, “Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat,” Pharmacology Biochemistry and Behavior, vol. 24, no. 3, pp. 525–529, 1986. View at: Publisher Site | Google Scholar
  36. B. Bakoma, B. Berké, K. Eklu-Gadegbeku et al., “Acute and sub-chronic (28days) oral toxicity evaluation of hydroethanolic extract of Bridelia ferruginea Benth root bark in male rodent animals,” Food and Chemical Toxicology, vol. 52, no. 82, 2013. View at: Google Scholar
  37. M. Slaoui, A. L. Bauchet, and L. Fiette, “Tissue sampling and processing for histopathology evaluation,” in Methods in Molecular Biology [Internet], Humana Press, Totowa, NJ, USA, 2017. View at: Google Scholar
  38. P. M. Richardson and J. B. Harborne, “Phytochemical methods: a Guide to modern Techniques of plant analysis. Second Edition,” Brittonia, vol. 42, no. 2, p. 115, 1990. View at: Publisher Site | Google Scholar

Copyright © 2021 Francis Ackah Armah et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.